188 related articles for article (PubMed ID: 22256846)
41. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff BB; Herman EH
Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
[TBL] [Abstract][Full Text] [Related]
42. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Tetef ML; Synold TW; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz HJ; Gandara D; Doroshow JH
Clin Cancer Res; 2001 Jun; 7(6):1569-76. PubMed ID: 11410492
[TBL] [Abstract][Full Text] [Related]
43. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
44. Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Aigner B; Bauernhofer T; Petru E; Niederkorn A; Arzberger EJ; Richtig E
Dermatology; 2014; 229(4):288-92. PubMed ID: 25472626
[TBL] [Abstract][Full Text] [Related]
45. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
46. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
47. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
48. Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
Mladosievicova B; Foltinová A; Petrásová H; Bernadic M; Hulín I
Neoplasma; 2001; 48(1):61-5. PubMed ID: 11327539
[TBL] [Abstract][Full Text] [Related]
49. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
50. Dimethyl sulfoxide therapy in the treatment of vesicant extravasation: two case presentations.
St Germain B; Houlihan N; D'Amato S
J Intraven Nurs; 1994; 17(5):261-6. PubMed ID: 7965372
[TBL] [Abstract][Full Text] [Related]
51. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Swain SM
Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
[TBL] [Abstract][Full Text] [Related]
52. Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation.
Lawrence HJ; Walsh D; Zapotowski KA; Denham A; Goodnight SH; Gandara DR
Cancer Chemother Pharmacol; 1989; 23(5):316-8. PubMed ID: 2706738
[TBL] [Abstract][Full Text] [Related]
53. Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.
Curtit E; Chaigneau L; Pauchot J; Nguyen T; Nerich V; Bazan F; Thiery-Vuillemin A; Demarchi M; Pivot X; Villanueva C
Anticancer Res; 2012 Apr; 32(4):1481-3. PubMed ID: 22493389
[TBL] [Abstract][Full Text] [Related]
54. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations.
Sparano JA
Semin Oncol; 1998 Aug; 25(4 Suppl 10):66-71. PubMed ID: 9768827
[TBL] [Abstract][Full Text] [Related]
55. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
56. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Bos AM; van der Graaf WT; Willemse PH
Acta Oncol; 2001; 40(4):541-2. PubMed ID: 11504316
[No Abstract] [Full Text] [Related]
57. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
Jones RL
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
[TBL] [Abstract][Full Text] [Related]
58. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
59. Clinical pharmacology of dexrazoxane.
Hochster HS
Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
[TBL] [Abstract][Full Text] [Related]
60. TopoTarget responds.
Parsons JL
Clin J Oncol Nurs; 2007 Dec; 11(6):789. PubMed ID: 18063535
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]